AN2 Therapeutics (ANTX) Accumulated Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Accumulated Expenses data on file, last reported at $613000.0 in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $613000.0, up 15.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $613000.0 (up 15.88% YoY), and the FY2025 annual result was $2.4 million, up 44.27% from the prior year.
• Accumulated Expenses retreated to $613000.0 in Q1 2026 per ANTX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $6.7 million in Q4 2023 and troughed at $10000.0 in Q2 2022.
• A 5-year average of $2.1 million and a median of $1.7 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 64330.0% in 2023, then sank 74.91% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $2.2 million in 2022, then surged by 208.16% to $6.7 million in 2023, then slumped by 74.91% to $1.7 million in 2024, then soared by 44.27% to $2.4 million in 2025, then tumbled by 74.65% to $613000.0 in 2026.
• Business Quant data shows ANTX's Accumulated Expenses at $613000.0 in Q1 2026, $2.4 million in Q4 2025, and $1.7 million in Q3 2025.